Why is ADAG down?
Down 12% on Nov 20, a down day for the market: the S&P 500 fell 4%, 84% of stocks fell, and biotech stocks a median 3%.
- Adagene fell 12% that day while biotech stocks fell a median 3%:
−2Long-term trend
Down 12% on Nov 20, a down day for the market: the S&P 500 fell 4%, 84% of stocks fell, and biotech stocks a median 3%.
−2Long-term trend
Follow ADAG's trial news. Pro members can get an alert when Adagene files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 42.5% more shares than a year ago |
| Latest filing | 6-K, Nov 19 |
$74.5M in cash
CFO Man Kin Tam bought 2,000 shares on Sep 23. 3 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ADAG is #196 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 196 |
Sales grew in four of the last seven years, to $7.7M in 2025. It lost money in each of the eight years.
RSI 39.5, MACD below signal, below both averages. Not scored.
3 insiders bought $162K across 5 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
“The biotechnology and pharmaceutical industries are highly competitive and characterized by continuing technological advancement, significant competition and an emphasis on intellectual property.”
ADAG scores -6 today, which Breakaway calls Poor. It is #196 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 12% on Nov 20, a down day for the market: the S&P 500 fell 4%, 84% of stocks fell, and biotech stocks a median 3%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ADAG scores -6 today, which Breakaway calls Poor (below zero). That is #196 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ADAG's -6.
3 insiders bought $162K across 5 filings in the last 6 months. No open-market sales on record. The newest is Man Kin Tam, Chief Financial Officer, who bought $6K on Sep 23. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.